Talphera (NASDAQ:TLPH – Get Free Report) issued its earnings results on Monday. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.14, Zacks reports.
Talphera Price Performance
Shares of Talphera stock opened at $0.50 on Tuesday. The firm has a 50 day simple moving average of $0.61 and a 200 day simple moving average of $0.71. Talphera has a fifty-two week low of $0.45 and a fifty-two week high of $1.27. The firm has a market cap of $8.43 million, a P/E ratio of -0.72 and a beta of 0.20.
Wall Street Analysts Forecast Growth
TLPH has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Talphera in a report on Tuesday. Rodman & Renshaw initiated coverage on shares of Talphera in a research note on Tuesday, January 28th. They issued a “buy” rating and a $4.00 target price for the company. Finally, RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a research report on Tuesday, January 28th.
About Talphera
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
Read More
- Five stocks we like better than Talphera
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Palantir Stock Builds Momentum on New Partnership
- Basic Materials Stocks Investing
- Tech Sell-Off Makes Microsoft Stock Look Like a Steal
- Find and Profitably Trade Stocks at 52-Week Lows
- Is Now the Right Time to Invest in a Natural Gas ETF?
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
